|
|
Article: Antares Receives First FDA Approval of ATD(TM) Gel Platform.
- Article from:
- Business Wire
- Article date:
- December 18, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Approval of Elestrin[TM] Triggers Approximately $2.6 Million Payment
EWING, N.J. -- Antares Pharma, Inc. (Amex: AIS) announced the U.S. Food and Drug Administration (FDA) approved for marketing Elestrin[TM] (formerly Bio-E-Gel[R]) in the United States. Antares' development partner, BioSante Pharmaceuticals (Amex: BPA) announced today that Bio-E-Gel will be marketed under the name Elestrin[TM] by Bradley Pharmaceuticals Inc. (NYSE: BDY) and is indicated for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause. Elestrin is the first FDA approved product in Antares' Advanced Transdermal Delivery (ATD[TM]) gel platform. Two ...